Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs BioNTech SE - ADR (BNTX) Price & Performance

BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

AES Corp vs BioNTech SE - ADR — how do they compare? AES Corp trades at $14.73 (market cap $10.49B), while BioNTech SE - ADR trades at $93.27 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 2.2× AES Corp's market cap, and AES Corp pays a 4.79% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

AESBNTX
Market Cap
$10.49B$23.31B
Sector
UtilitiesHealth
52-Week High
$17.28$119.34
52-Week Low
$12.51$83.89
Enterprise Value
$40.75B$6.60B
Dividend Yield
4.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.73, down slightly by 0.03%, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 14.34% net income margin and 45.05% ROE, supported by recent earnings beats. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders in June 2026, dominates recent news, alongside a quarterly dividend of $0.18 per share.

The outlook is heavily influenced by the acquisition, offering a near-term upside to the $15 buyout price, but regulatory and shareholder approval risks remain. Long-term fundamentals are solid with projected revenue growth to $13.1 billion in 2026, though high debt levels and integration challenges post-acquisition pose risks. Analyst sentiment is mixed with a buy consensus of 43%.

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Returns comparison

Trailing returns across standard periods

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX